Case Based Peer Perspectives

Neeta Somaiah, MD, reviews the case of a 68-year-old man with gastrointestinal stromal tumor.

Ramez N. Eskander, MD, explains the rationale for treating a 71-year-old woman with ovarian cancer with the PARP inhibitor rucaparib upon relapse.

Pierre Gholam, MD, provides insight on the case of a 61-year-old man with stage 4 hepatocellular carcinoma and evaluates current treatment options on TKIs.

Margaret von Mehren, MD, describes the rationale for treating a man with GIST with ripretinib as fourth-line therapy.

Christopher Flowers, MD, describes the management of an elderly patient with relapsed follicular lymphoma using newer novel therapy.

Kami Maddocks, MD, reviews the case of a 76-year-old woman with stage 4 mantle cell lymphoma and evaluates the role of BTK inhibitors in the treatment of relapsed/refractory disease.

Expert perspectives on the identification and management of metastatic castrate-sensitive prostate cancer in a 67-year-old man.

Danielle M. Brander, MD, remarks on the appropriateness for targeted therapy as a treatment option for a 73-year-old man with relapsed chronic lymphocytic leukemia.

Anthony El-Khoueiry, MD, provides insight on the case of a 69-year-old man with stage 4 hepatocellular carcinoma and evaluates current and emerging treatment options.

Evan Y. Yu, MD, discusses the case and subsequent palliative treatment plan for a patient with metastatic castration-resistant prostate cancer.

Ramez Eskander, MD, presents the case of a 68-year-old woman with stage IV ovarian cancer, and discusses the management approach for this patient and similar cases.

Ajay K. Gopal, MD, discusses the rationale for treating a 69-year-old woman with high-risk follicular lymphoma with a PI3-kinase inhibitor in the third-line setting.

Corey S. Cutler, MD, MPH, FRCPC, provides insight on the case of a 49-year-old man with chronic GVHD and reviews current and emerging treatment options for disease management.

John Heymach, MD, reviews the evolving treatment landscape of EGFR+ metastatic non-small cell lung cancer.

Jorge Garcia, MD, FACP, provides insight on the case of a 69-year-old man with mCRPC and assesses the classes of agents currently available as treatment options.

Recommendations for treating a 68-year-old male with mantle cell lymphoma with a BTK inhibitor once he has relapsed on prior therapy.

Cathy Eng, MD, FACP, FASCO, reviews the case of a 68-year-old diagnosed with metastatic NTRK fusion-positive colon cancer and shares treatments options.

Usama Gergis, MD, presents the case of a 61-year old man with GvHD, and provides an overview of available treatment options for similar patients, with consideration of the REACH1, REACH2, and GRAVITAS-301 trial regimens.

Luis Raez, MD, reviews the case of a 67-year-old man with metastatic non-small cell NTRK gene fusion lung cancer.

A 59-Year-Old Woman With HER2+ De Novo Metastatic Breast Cancer

A 59-Year Old Woman With Stage IIIC Ovarian Cancer

A 69-Year Old Man With Metastatic BRAF V600E-Mutated Metastatic NSCLC

A 54-Year-Old Woman With Stage 2 HER2+ Breast Cancer

A 62-Year-Old Woman With Metastatic BRAF V600E-Mutated NSCLC

A 63-Year-Old Woman With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

A 75-Year-Old Man With Metastatic Castrate-Resistant Prostate Cancer

A 60-Year Old Man With Untreated Stage IV EGFR-Mutated Non-Small Cell Lung Cancer

A 72-Year-Old Man With Symptomatic Follicular Lymphoma

A 62-Year-Old Male With Stage III Non-Small Cell Lung Cancer

A 64-Year-Old Male with Untreated Stage IV EGFR-Mutated NSCLC